EUCTR2015-004099-31-BE进行中（未招募）1 期
ong-term persistence of immunity to hepatitis B in adults vaccinated 20 to 30 years ago with Engerix™-B. - HBV-322
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •- A male or female between and including 40 and 60 years of age (from and including the 40th birthday up to, but excluding, the 61st birthday) at the time of the vaccination.
- •- Written informed consent obtained from the subject.
- •- Documented evidence of previous vaccination with three or four consecutive doses of Engerix-B administered in adulthood (i.e. at least 18 years of age) with
- •- the last dose received 4 to 12 months after the previous one,
- •- no subsequent booster dose ever received later, and
- •- the last dose received 20 to 30 years before enrolment.
- •- Female subjects of non-childbearing potential may be enrolled in the study.
- •- Non-childbearing potential is defined as pre-menarche, hysterectomy, ovariectomy or post-menopause.
- •- Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •- has practiced adequate contraception for 30 days prior to vaccination, and
- •- has a negative pregnancy test on the day of vaccination, and
- •- has agreed to continue adequate contraception during the entire treatment period and for one month after vaccination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before the dose of study vaccine, or planned use during the study period.
- •- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose. For corticosteroids, this will mean prednisone = 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
- •- Administration of long-acting immune-modifying drugs at any time during the study period.
- •- Previous hepatitis B booster vaccination since completion of the primary vaccination series with three or four doses of Engerix-B.
- •- Planned administration of a vaccine not foreseen by the study protocol within 30 days preceding the dose of study vaccine, or planned administration during the study period, with the exception of seasonal influenza vaccine.
- •- Any medical condition that in the judgment of the investigator places the subject at undue risk by participating in the study.
- •- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
- •- History of hepatitis B disease or episode of jaundice with unknown etiology.
- •- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
- •- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •- Major congenital defects or serious chronic illness (including insulin-dependent diabetes).
- •- Acute disease and/or fever at the time of enrolment.
- •-Fever is defined as temperature = 37.5°C for oral, axillary or tympanic route, or 38.0°C on rectal route.
- •- Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
- •- Administration of immunoglobulins and/or any blood products during the period starting 3 months before the dose of study vaccine, or planned administration during the study period.
- •- Drug and/ or alcohol abuse within the last 5 years.
研究者
相似试验
进行中（未招募）
1 期
A phase IV, open-label, multi-centre study to assess the long-term persistence of hepatitis A and B antibodies in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined hepatitis A and B vaccine, Twinrix® (SB208127) in study HAB-084 (208127/084).Healthy volunteers (Vaccination against hepatitis A and hepatitis B in healthy adults)MedDRA version: 16.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-004586-13-BEGlaxoSmithKline Biologicals180
进行中（未招募）
不适用
An open-label, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immunogenicity and safety study of a single dose hepatitis B (Engerix™-B Kinder) vaccine challenge in adolescents aged 12-13 years, previously primed and boosted in the first two years of life with four doses of GSK Biologicals’ DTPa-HBV-IPV/Hib (Infanrix™ hexa) vaccine.Hepatitis BEUCTR2013-002821-41-DEGlaxoSmithKline Biologicals
进行中（未招募）
1 期
A study to evaluate persistence of hepatitis B antibodies, immunogenicity and safety of Engerix™-B Kinder challenge dose, in adolescents vaccinated with four doses of Infanrix™ hexa during infancy.Immunisation against infection caused by all known subtypes of hepatitis B virus.MedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-003391-74-DEGlaxoSmithKline Biologicals300
已完成
4 期
Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-BHepatitis B VaccineNCT02901951GlaxoSmithKline106
已完成
4 期
This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ HexaHepatitis BNCT02052661GlaxoSmithKline301